ClinicalTrials.gg
CompletedNCT01114893Updated Jun 23, 2011Results posted

Travoprost Five Day Posology Study

A Phase 2 interventional study of Travoprost 0.004% and Travoprost Vehicle in Open-angle Glaucoma (OAG) and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-23.

Sponsored by Alcon Research (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
33rd of 45
60 · median 135
Started
2010
with 2 others
Phase 2
6 of 46
none open now
Registered
24th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 33rd largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2010, is one of 6 in phase 2, and was the 24th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.

03

Conditions studied

  • Open-angle Glaucoma (OAG)
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. either sex and any race/ethnicity, ≥18 years old
  2. diagnosed with open-angle glaucoma, and/or ocular hypertension
  3. meets the following IOP entry criteria:

    • Mean IOP ≥ 24 millimeters mercury (mmHg) in at least 1 eye, with the same eye qualifying at 8 AM on both the Eligibility Visit (Day 0) and Day 1
    • Mean IOP ≤ 36 mmHg in both eyes at 8 AM and 8 PM at the Eligibility Visit (Day 0), and at 8 AM on Day 1
  4. satisfies all requirements; able to read, sign and date the informed consent

Exclusion criteria

Exclusion Criteria:

  1. females of not meeting protocol conditions
  2. angle grade less than Grade 2 in either eye
  3. cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye
  4. severe central visual field loss in either eye
  5. any abnormality preventing reliable applanation tonometry in either eye
  6. to prostaglandin analogues or to any component of the study medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    TRAVATAN

    TRAVATAN 0.004% once daily

    Drug: Travoprost 0.004%

  • Placebo comparator
    Travoprost Vehicle

    Travoprost Vehicle

    Drug: Travoprost Vehicle

  • Experimental
    Travoprost Group A

    Travoprost Group A

    Drug: Travoprost (Groups A, B and C)

  • Experimental
    Travoprost Group B

    Travoprost Group B

    Drug: Travoprost (Groups A, B and C)

  • Experimental
    Travoprost Group C

    Travoprost Group C

    Drug: Travoprost (Groups A, B and C)

Interventions

  • 1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days

  • DrugTravoprost Vehicle

    1 drop in each eye 8 times daily for 5 days

  • DrugTravoprost (Groups A, B and C)

    Drug page: Travoprost

    1 drop in each eye 8 times daily for 5 days

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5

    Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment

    Time frame: 5 days

Secondary outcomes

  1. IOP Change From Baseline at 8 PM on Day 5

    Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment

    Time frame: 5 Days

07

Results

Posted Jun 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneTRAVATANTravoprost VehicleTravoprost Group ATravoprost Group BTravoprost Group C
Started1414141312
Completed1414141312
Not completed00000

Outcome measures

PrimaryMean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5

Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment

Time frame:
5 days
Reported as:
Mean · mm Hg
Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5
mm HgTravatan 0.004% QDTravoprost VehicleTravoprost Group ATravoprost Group BTravoprost Group C
Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5-9.8 (-12.5 to -7.0)-2.9 (-4.7 to -1.0)-5.0 (-6.7 to -3.3)-6.5 (-8.7 to -4.4)-6.8 (-8.5 to -5.0)
SecondaryIOP Change From Baseline at 8 PM on Day 5

Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment

Time frame:
5 Days
Reported as:
Mean · mm Hg
IOP Change From Baseline at 8 PM on Day 5
mm HgTravatan 0.004% QDTravoprost VehicleTravoprost Group ATravoprost Group BTravoprost Group C
IOP Change From Baseline at 8 PM on Day 5-3.9 (-6.2 to -1.5)-0.9 (-2.6 to 0.7)-2.7 (-4.3 to -1.2)-5.7 (-7.5 to -3.9)-4.8 (-6.1 to -3.6)

Adverse events

Collected over 1 month. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TRAVATAN—0/14 (0%)8/14 (57.1%)
Travoprost Vehicle—0/14 (0%)2/14 (14.3%)
Travoprost Group A—0/14 (0%)5/14 (35.7%)
Travoprost Group B—0/13 (0%)8/13 (61.5%)
Travoprost Group C—0/12 (0%)6/12 (50%)
Most frequent other events
Most frequent other events
EventTRAVATANTravoprost VehicleTravoprost Group ATravoprost Group BTravoprost Group C
Ocular HyperaemiaEye disorders4/140/145/145/135/12
PhotophobiaEye disorders0/140/140/143/130/12
Eye PruritusEye disorders2/141/141/142/130/12
Vision BlurredEye disorders0/140/140/140/131/12
Corneal StainingEye disorders1/141/141/140/131/12
Dry EyeEye disorders1/140/141/141/130/12
Eye IrritationEye disorders0/140/140/141/130/12
Foreign Body SensationEye disorders1/140/140/140/130/12
HeadacheEye disorders1/140/140/140/130/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TRAVATANTravoprost VehicleTravoprost Group ATravoprost Group BTravoprost Group CTotal
<=18 years000000
Between 18 and 65 years8894332
>=65 years6659935
Sex: Female, Male
Sex: Female, Male(Participants)TRAVATANTravoprost VehicleTravoprost Group ATravoprost Group BTravoprost Group CTotal
Female7769837
Male7784430
08

Study locations

1 site
  • Contact Alcon Call Center For Trial Locations
    Fort Worth, Texas 76134, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010 and a primary completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2010
First posted
May 3, 2010
Start
Apr 2010
Primary completionActual
May 2010
Results first posted
Jun 23, 2011
Last update
Jun 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01114893
Lead sponsor
Alcon Research
First posted
May 3, 2010
Start date
Apr 2010
Primary completion
May 2010
Results posted
Jun 23, 2011
Last update
Jun 23, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion